Long-Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55 Years | Clinical Pharmacy and Pharmacology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Rapp  SR, Espeland  MA, Shumaker  SA,  et al; WHIMS Investigators.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial.  JAMA. 2003;289(20):2663-2672.PubMedGoogle ScholarCrossref
Espeland  MA, Rapp  SR, Shumaker  SA,  et al; Women’s Health Initiative Memory Study.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study.  JAMA. 2004;291(24):2959-2968.PubMedGoogle ScholarCrossref
Espeland  MA, Brunner  RL, Hogan  PE,  et al; Women’s Health Initiative Study of Cognitive Aging Study Group.  Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women’s Health Initiative study of cognitive aging extension.  J Am Geriatr Soc. 2010;58(7):1263-1271.PubMedGoogle ScholarCrossref
Resnick  SR, Espeland  MA, Jaramillo  SA,  et al.  Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study.  Neurology. 2009;72(2):135-142.PubMedGoogle ScholarCrossref
Espeland  MA, Tindle  HA, Bushnell  CA,  et al; Women’s Health Initiative Memory Study.  Brain volumes, cognitive impairment, and conjugated equine estrogens.  J Gerontol A Biol Sci Med Sci. 2009;64(12):1243-1250.PubMedGoogle ScholarCrossref
Henderson  VW, Benke  KS, Green  RC, Cupples  LA, Farrer  LA; MIRAGE Study Group.  Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age.  J Neurol Neurosurg Psychiatry. 2005;76(1):103-105.PubMedGoogle ScholarCrossref
Whitmer  RA, Quesenberry  CP, Zhou  J, Yaffe  K.  Timing of hormone therapy and dementia: the critical window theory revisited.  Ann Neurol. 2011;69(1):163-169.PubMedGoogle ScholarCrossref
Shao  H, Breitner  JCS, Whitmer  RA,  et al; Cache County Investigators.  Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study.  Neurology. 2012;79(18):1846-1852.PubMedGoogle ScholarCrossref
Daniel  JM, Bohacek  J.  The critical period hypothesis of estrogen effects on cognition: insights from basic research.  Biochim Biophys Acta. 2010;1800(10):1068-1076.PubMedGoogle ScholarCrossref
Barrett-Connor  E, Laughlin  GA.  Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials.  Semin Reprod Med. 2009;27(3):275-282.PubMedGoogle ScholarCrossref
Hogervorst  E, Bandelow  S.  Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials.  Maturitas. 2010;66(1):56-71.PubMedGoogle ScholarCrossref
Taylor  HS, Manson  JE.  Update in hormone therapy use in menopause.  J Clin Endocrinol Metab. 2011;96(2):255-264.PubMedGoogle ScholarCrossref
The Women’s Health Initiative Study Group.  Design of the Women’s Health Initiative clinical trial and observational study.  Control Clin Trials. 1998;19(1):61-109.PubMedGoogle ScholarCrossref
Rossouw  JE, Anderson  GL, Prentice  RL,  et al; Writing Group for the Women’s Health Initiative Investigators.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.  JAMA. 2002;288(3):321-333.PubMedGoogle ScholarCrossref
Anderson  GL, Limacher  M, Assaf  AR,  et al; Women’s Health Initiative Steering Committee.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.  JAMA. 2004;291(14):1701-1712.PubMedGoogle ScholarCrossref
Rapp  SR, Legault  C, Espeland  MA,  et al; CAT Study Group.  Validation of a cognitive assessment battery administered over the telephone.  J Am Geriatr Soc. 2012;60(9):1616-1623.PubMedGoogle ScholarCrossref
de Jager  CA, Budge  MM, Clarke  R.  Utility of TICS-M for the assessment of cognitive function in older adults.  Int J Geriatr Psychiatry. 2003;18(4):318-324.PubMedGoogle ScholarCrossref
Shumaker  SA, Reboussin  BA, Espeland  MA,  et al.  The Women’s Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia.  Control Clin Trials. 1998;19(6):604-621.PubMedGoogle ScholarCrossref
Albert  M, Smith  LA, Scherr  PA, Taylor  JO, Evans  DA, Funkenstein  HH.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease.  Int J Neurosci. 1991;57(3-4):167-178.PubMedGoogle ScholarCrossref
Reitan  R.  Trail Making Test: Manual for Administration and Scoring. Tucson, AZ: Reitan Neuropsychological Laboratory; 1975.
Mrazik  M, Millis  S, Drane  DL.  The oral trail making test: effects of age and concurrent validity.  Arch Clin Neuropsychol. 2010;25(3):236-243.PubMedGoogle ScholarCrossref
Benton  A.  Differential behavioral effects in frontal lobe disease.  Neuropsychologia. 1968;6:53-60.Google ScholarCrossref
Wechsler  D.  Manual for the Wechsler Adult Intelligence Scale-Revised WAIS-R. New York, NY: Psychological Corporation; 1981.
Littell  RC, Milliken  GA, Stroup  WW, Wolfinger  RD.  SAS System for Mixed Models. Cary, NC: SAS Institute, Inc; 1996.
Delis  DC, Kramer  J, Kaplan  E.  The California Verbal Learning Test. New York, NY: The Psychological Corporation; 1987.
Ryan  J, Carrière  I, Scali  J, Ritchie  K, Ancelin  ML.  Life-time estrogen exposure and cognitive functioning in later life.  Psychoneuroendocrinology. 2009;34(2):287-298.PubMedGoogle ScholarCrossref
Kang  JH, Grodstein  F.  Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline.  Neurobiol Aging. 2012;33(7):1129-1137.PubMedGoogle ScholarCrossref
Almeida  OP, Lautenschlager  NT, Vasikaran  S, Leedman  P, Gelavis  A, Flicker  L.  A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life.  Neurobiol Aging. 2006;27(1):141-149.PubMedGoogle ScholarCrossref
Grady  D, Yaffe  K, Kristof  M, Lin  F, Richards  C, Barrett-Connor  E.  Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study.  Am J Med. 2002;113(7):543-548.PubMedGoogle ScholarCrossref
Laughlin  GA, Kritz-Silverstein  D, Barrett-Connor  E.  Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study.  Clin Endocrinol (Oxf). 2010;72(1):99-106.PubMedGoogle ScholarCrossref
Rocca  WA, Grossardt  BR, Shuster  LT, Stewart  EA.  Hysterectomy, oophorectomy, estrogen, and the risk of dementia.  Neurodegener Dis. 2012;10(1-4):175-178.PubMedGoogle ScholarCrossref
Sherwin  BB.  Estrogen and cognitive aging in women.  Neuroscience. 2006;138(3):1021-1026.PubMedGoogle ScholarCrossref
Evans  DA, Grodstein  F, Loewenstein  D, Kaye  J, Weintraub  S.  Reducing case ascertainment costs in U.S. population studies of Alzheimer’s disease, dementia, and cognitive impairment—Part 2.  Alzheimers Dement. 2011;7(1):110-123.PubMedGoogle ScholarCrossref
Shumaker  SA, Legault  C, Kuller  L,  et al; Women’s Health Initiative Memory Study.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study.  JAMA. 2004;291(24):2947-2958.PubMedGoogle ScholarCrossref
Espeland  MA, Pettinger  M, Falkner  KL,  et al Demographic and health factors associated with enrollment in posttrial studies: The Women’s Health Initiative Hormone Therapy trials [published online March 12, 2013].  Clin Trials. doi:10.1177/1740774513477931.Google Scholar
Original Investigation
August 12/26, 2013

Long-Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55 Years

Author Affiliations
  • 1Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • 2Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • 3Division of Preventive Medicine, Department of Epidemiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • 5Center for Health Research, Kaiser-Permanente Northwest, Portland, Oregon
  • 6Division of Cardiology, Departments of Epidemiology and Medicine, University of Iowa, Iowa City
  • 7Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • 8Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee
  • 9Department of Preventive Medicine, Stony Brook University, State University of New York, Stony Brook
  • 10Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo
  • 11Department of Medicine, Prevention Research Center, Stanford University, Palo Alto, California
  • 12Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester
  • 13Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
JAMA Intern Med. 2013;173(15):1429-1436. doi:10.1001/jamainternmed.2013.7727

Importance  Postmenopausal hormone therapy with conjugated equine estrogens (CEEs) may adversely affect older women’s cognitive function. It is not known whether this extends to younger women.

Objective  To test whether prescribing CEE-based hormone therapy to postmenopausal women aged 50 to 55 years has longer-term effects on cognitive function.

Design  Trained, masked staff assessed participants with an annual telephone-administered cognitive battery that included measures of global and domain-specific cognitive functions. Cognitive testing was conducted an average of 7.2 years after the trials ended, when women had a mean age of 67.2 years, and repeated 1 year later. Enrollment occurred from 1996 through 1999.

Setting  Forty academic research centers.

Participants  The study population comprised 1326 postmenopausal women, who had begun treatment in 2 randomized placebo-controlled clinical trials of hormone therapy when aged 50 to 55 years.

Intervention  The clinical trials in which the women had participated had compared 0.625 mg CEE with or without 2.5 mg medroxyprogesterone acetate over a mean of 7.0 years.

Main Outcomes and Measures  The primary outcome was global cognitive function. Secondary outcomes were verbal memory, attention, executive function, verbal fluency, and working memory.

Results  Global cognitive function scores from women who had been assigned to CEE-based therapies were similar to those from women assigned to placebo: mean (95% CI) intervention effect of 0.02 (−0.08 to 0.12) standard deviation units (P = .66). Similarly, no overall differences were found for any individual cognitive domain (all P > .15). Prespecified subgroup analyses found some evidence that CEE-based therapies may have adversely affected verbal fluency among women who had prior hysterectomy or prior use of hormone therapy: mean treatment effects of −0.17 (−0.33 to −0.02) and −0.25 (−0.42 to −0.08), respectively; however, this may be a chance finding.

Conclusions and Relevance  CEE-based therapies produced no overall sustained benefit or risk to cognitive function when administered to postmenopausal women aged 50 to 55 years. We are not able to address whether initiating hormone therapy during menopause and maintaining therapy until any symptoms are passed affects cognitive function, either in the short or longer term.

Trial Registration  clinicaltrials.gov Identifier: NCT01124773